Assignee profile:

MicroVAX, LLC

City:

Warrenton, Virginia

Country:

United States

Published Applications:

20

Last publication date:

2025-09-30

Patent Grants:

20

Last grant date:

2025-09-30

Top Inventors for applications by MicroVAX, LLC

These are the the leading inventors for applications assigned to MicroVAX, LLC:

Recent patent applications by MicroVAX, LLC

MicroVAX, LLC based in Warrenton, US has been assigned the rights to these inventions. The list includes both Pending Applications and Patent Grants:

#1 | 2025-09-30 ✅ Patent 12,427,191 granted on 2025-09-30
US17726801
Human necessities

SARS-CoV-2 fusion protein vaccine/regimen

#2 | 2021-10-26 ✅ Patent 11,154,603 granted on 2021-10-26
US15864268
Human necessities

Burkholderia pseudomallei composition

#3 | 2020-02-13 ✅ Patent 10,835,589 granted on 2020-11-17
US20200046820A1
Human necessities

Vaccine directed to induction of immune response to protein and glycolipid antigens of bacterial cells through interaction of CD40L/CD40 receptor axis with complex of glycolipid/CD1d receptor in NKT cells and in dendritic cells

#4 | 2019-10-01 ✅ Patent 10,426,827 granted on 2019-10-01
US14724409
Human necessities

Dengue hemorrhagic fever virus vaccine

#5 | 2019-05-21 ✅ Patent 10,293,040 granted on 2019-05-21
US14695445
Human necessities

Pharmaceutical compositions and methods of blocking

#6 | 2019-03-07 ✅ Patent 11,839,655 granted on 2023-12-12
US20190070289A1
Human necessities

Combination cancer therapy

#7 | 2019-01-22 ✅ Patent 10,183,067 granted on 2019-01-22
US15587777
Human necessities

TAA/CD4OL composition/vaccine for malaria

#8 | 2019-01-08 ✅ Patent 10,174,100 granted on 2019-01-08
US14822178
Chemistry; metallurgy

Multivalent DNA composition for

#9 | 2019-01-01 ✅ Patent 10,166,284 granted on 2019-01-01
US15689386
Human necessities

Vaccines for herpes simplex virus 1 and 2

#10 | 2018-12-11 ✅ Patent 10,149,899 granted on 2018-12-11
US15375455
Human necessities

Composition and method against C-difficile

#11 | 2018-11-20 ✅ Patent 10,130,667 granted on 2018-11-20
US15130041
Human necessities

TAA/ecdCD40L oncolytic virus

#12 | 2018-02-13 ✅ Patent 9,889,188 granted on 2018-02-13
US15341389
Human necessities

Ebola virus composition/vaccine

#13 | 2017-08-24 ✅ Patent 10,383,932 granted on 2019-08-20
US20170239339A1
Human necessities

Vaccine directed to induction of immune response to protein and glycolipid antigens of bacterial cells through interaction of CD4OL/CD40 receptor axis with complex of glycolipid/CD1d receptor in NKT cells and in dendritic cells

#14 | 2017-06-29 ✅ Patent 11,077,183 granted on 2021-08-03
US20170182147A1
Human necessities

CD40 ligand fusion protein vaccine

#15 | 2017-06-29 ✅ Patent 10,046,041 granted on 2018-08-14
US20170182145A1
Human necessities

Methods and compositions for suppressing virulence of methicillin resistant

#16 | 2017-01-19 ✅ Patent 9,757,438 granted on 2017-09-12
US20170014497A1
Human necessities

Mucin antigen vaccine

#17 | 2016-12-27 ✅ Patent 9,526,774 granted on 2016-12-27
US14690889
Human necessities

Methods and compositions for suppressing virulence of methicillin resistant

#18 | 2015-03-05 ✅ Patent 9,353,167 granted on 2016-05-31
US20150064209A1
Chemistry; metallurgy

Methods for generating immunity to antigen

#19 | 2014-10-30 ✅ Patent 9,402,920 granted on 2016-08-02
US20140322301A1
Human necessities

Mucin antigen vaccine

#20 | 2007-06-07 ✅ Patent 9,533,036 granted on 2017-01-03
US20070128223A1
Human necessities

Methods for generating immune responses to influenza antigens with a secretable CD40L fusion protein

Also check out MicroVAX, LLC's (Warrenton, United States) applicant profile with 10 patent applications submitted.

AssigneeID:

508412 ⎘